SUVOREXANT

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category UNKNOWN
ATC N05CM19
UNII 081L192FO9
EPA CompTox DTXSID90145616

Structure

InChI Key JYTNQNCOQXFQPK-MRXNPFEDSA-N
Smiles Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1
InChI
InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H23ClN6O2
Molecular Weight 450.93
AlogP 4.11
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 3.0
Polar Surface Area 80.29
Molecular species NEUTRAL
Aromatic Rings 4.0
Heavy Atoms 32.0

Bioactivity

Mechanism of Action Action Reference
Orexin receptor antagonist ANTAGONIST FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Orexin receptor
- 0-138 - 0-3 -
Assay Description Organism Bioactivity Reference
Displacement of [3H](S)-N-(biphenyl-2-yl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX1R expressed in CHO cells after 3 hrs by scintillation counting Homo sapiens 0.55 nM
Displacement of [3H]N-cyclobutyl-5-methyl-N-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)ethyl)-2-(2H-1,2,3-triazol-2-yl)benzamide from human OX1R expressed in CHO cells after 20 hrs by scintillation counting Homo sapiens 0.55 nM
Displacement of [3H](S)-N-(2-(1H-pyrrol-1-yl)phenyl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX2R expressed in CHO cells after 3 hrs by scintillation counting Homo sapiens 0.35 nM
Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay Homo sapiens 50.0 nM
Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay Homo sapiens 56.0 nM
Binding affinity to orexin receptor 1 (unknown origin) Homo sapiens 0.6 nM
Binding affinity to orexin receptor 2 (unknown origin) Homo sapiens 0.4 nM
Antagonist activity at mouse OX2 receptor expressed in HEK cells assessed as inhibition of orexin A-induced Ca2+ accumulation after 1 hr by Fluo-4-AM staining-based FLIPR assay Mus musculus 8.71 nM
Antagonist activity at mouse OX1 receptor expressed in CHO cells assessed as inhibition of orexin A-induced Ca2+ accumulation after 1 hr by Fluo-4-AM staining-based FLIPR assay Mus musculus 1.698 nM
Displacement of [3H]radioligand from human orexin-1 receptor expressed in CHO cells after 3 hrs by scintillation counting analysis Homo sapiens 0.6 nM
Displacement of [3H]radioligand from human orexin-2 receptor expressed in CHO cells after 3 hrs by scintillation counting analysis Homo sapiens 0.4 nM
Antagonist activity at human orexin-1 receptor expressed in CHO cells assessed as inhibition of Ala-6, 12-induced responses by FLIPR assay Homo sapiens 50.0 nM
Antagonist activity at human orexin-2 receptor expressed in CHO cells assessed as inhibition of Ala-6, 12-induced responses by FLIPR assay Homo sapiens 56.0 nM
Displacement of [125I]-Orexin A from human OX2R expressed in CHO cells after 30 mins by topcount analysis Homo sapiens 11.8 nM
Antagonist activity at human orexin 1 receptor Ile408-Val mutant expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium level after 60 mins by FLIPR assay Homo sapiens 0.6 nM
Antagonist activity at human orexin 2 receptor expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium level after 60 mins by FLIPR assay Homo sapiens 0.4 nM
Antagonist activity at OX2R (unknown origin) Homo sapiens 56.0 nM
Antagonist activity at OX1R (unknown origin) Homo sapiens 50.0 nM
Antagonist activity at human orexin 1 receptor expressed in HEK293 cells assessed as inhibition of orexin-induced calcium mobilization after 60 mins by FLIPR assay Homo sapiens 199.0 nM
Antagonist activity at human orexin 2 receptor expressed in HEK293 cells assessed as inhibition of orexin-induced calcium mobilization after 60 mins by FLIPR assay Homo sapiens 138.0 nM
Displacement of [3H]4-(2,6-Difluoro-4-methoxybenzyl)-2-(5,6-dimethoxypyridin-3-yl)-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide from human wild-type OX1 receptor expressed in baculovirus infected Sf21 insect cell membranes measured after 90 mins by liquid scintillation counting method Homo sapiens 0.3981 nM
Displacement of [3H]4-(2,6-Difluoro-4-methoxybenzyl)-2-(5,6-dimethoxypyridin-3-yl)-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide from human wild-type OX2 receptor expressed in baculovirus infected Sf21 insect cell membranes measured after 90 mins by liquid scintillation counting method Homo sapiens 0.7943 nM
Displacement of [3H]-SB67404 from human orexin 1 receptor expressed in CHO cells incubated for 2 hrs by whole cell radioligand binding assay Homo sapiens 3.09 nM
Displacement of [3H]-EMPA from human orexin 2 receptor expressed in CHO cells incubated for 2 hrs by whole cell radioligand binding assay Homo sapiens 2.951 nM

Cross References

Resources Reference
ChEBI 82698
ChEMBL CHEMBL1083659
DrugBank DB09034
DrugCentral 4881
FDA SRS 081L192FO9
Guide to Pharmacology 2890
PDB SUV
PubChem 24965990
SureChEMBL SCHEMBL1586289
ZINC ZINC000049036447
CONTENTS